• DOI:10.1200/jco.2012.30.5_suppl.63
• Corpus ID: 9479933

Evaluation of circulating tumor cells (CTCs) enumeration and 18F-Choline positron emission tomography/computed tomography (FCH PET/CT) as early efficacy response biomarkers in metastatic castration-resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate.

@article{LeMoulec2012EvaluationOC,
  title={Evaluation of circulating tumor cells (CTCs) enumeration and 18F-Choline positron emission tomography/computed tomography (FCH PET/CT) as early efficacy response biomarkers in metastatic castration-resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate.},
  author={Sylvestre Le Moulec and Christophe Massard and Eric Gontier and Françoise Farace and Cyrus Chargari and Philippe Vielh and Olivier Aup{\'e}e and Lionel V{\'e}drine and Herv{\'e} Foehrenbach and Karim Fizazi},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 5\_suppl},
  pages={63},
  url={https://api.semanticscholar.org/CorpusID:9479933}
}

• S. Le Moulec, C. Massard, +7 authors K. Fizazi
• Published in Journal of Clinical Oncology 10 February 2012
• Medicine

TLDR

Assessment of prostate specific antigen, CTC and FCH PET/CT in metastatic CRPC pts receiving recently approved abiraterone acetate therapy after chemotherapy indicates discrepancy in 45% with response assessment using PSA.Expand